Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 380 employees. About 70% of the employees and projects are externally funded. Read more
See introductory video with welcome to the ICR
The European Joint Action on Personalised Cancer Medicine officially launched on January 14, bringing together 29 European countries and over 140 partner organisations to advance personalised cancer care across Europe. Coordinated by the Belgian public health institute Sciensano, the project aims to create a sustainable cross-border network to foster innovation, equity, and collaboration in personalised cancer prevention, diagnosis, treatment, follow-up and tertiary prevention.
Oslo University Hospital (OUS) serves as the Norwegian coordinator.
"RNA Therapeutics: From siRNA to mRNA Innovations", edited by Mouldy Sioud and published by Springer Nature, presents a comprehensive and authoritative overview of the scientific advances driving the rapid growth of RNA-based therapeutics. This landmark volume brings together leading international experts to explore the evolution of RNA technologies and their expanding role in modern medicine.
Mouldy Sioud leads the Immunomodulation and Targeted Therapies research group at the Department of Cancer Immunology at the Institute for Cancer Research.
Recommended sites for current OUS research news:
From Oslo University Hospital, in Norwegian:
OUS Innsikt – ny forskning, innovasjon og behandling - channel for science communication
More news from OUS (oslo-universitetssykehus.no)
From centres of excellence (UiO/OUS):
CanCell - Centre for Cancer Cell Reprogramming
Cresco - Centre for Embryology and Healthy Development
PRIMA - Precision Immunotherapy Alliance - Norwegian version
Hybrid Technology Hub - Centre for Organ on a Chip-Technology
Oslo University Hospital hereby announce research awards in the following two catagories for 2026:
Closing date for nominations: March 2nd 2026.
Before the Christmas break, the major Norwegian TV channel TV2 visited the Radium Hospital to learn about the Pseudovax trial. The first patient that recived the vaccine, Mette, was the main focus, together with comments from general secretary Ingrid Stenstadvold Ross in the Norwegian Cancer Society and Kjersti Flatmark, one of the lead investigators of the study.
The Pseudovax clinical trial will evaluate a novel cancer vaccine developed at the Norwegian Radium Hospital specifically for patients with Pseudomyxoma peritonei (PMP) .
"If the vaccine proves to be effective, we hope that this could become an new treatment option for patients with PMP who are not cured by surgery", Flatmark says.
Thomas Fleischer, project leader at Institute for Cancer Research (ICR), Oslo University Hospital, has been awarded the Researcher of the Year 2025 prize by the ICR leadership.
The prize was presented at the Institute seminar on December 17 and includes a personal scholarship of 100,000 NOK funded by the Radium Hospital Foundation to support further research excellence.
